• News
  • SAN DIEGO
  • Health

Neurocrine Biosciences granted two patents

Neurocrine Biosciences Inc. (Nasdaq: NBIX) has announced that two more patents have been granted related to the company's proprietary Vesicular Monoamine Transporter 2 inhibitor, a protein concentrated in the human brain that is primarily responsible for re-packaging and transporting monoamines, like dopamine, norepinephrine, serotonin and histamine, among nerve cells.

One patent, issued by the European Patent Office, covers chemical compositions, pharmaceutical compositions and uses of various compounds, including Neurocrine's Phase 2b clinical candidate NBI-98854. That patent has an expiration date of November 2027.

In addition to the already issued composition of matter patent, the U.S. Patent and Trademark Office also has granted a patent for NBI-98854, covering the method of treating hyperkinetic movement disorders. It also will expire in November 2027.

"This EU patent, coupled with our new United States methods of use patent, and the existing United States composition of matter patent provide a strong intellectual property estate around NBI-98854," said Kevin Gorman, CEO of Neurocrine Biosciences. "We intend to continue to expand our VMAT2 patent footprint on NBI-98854 and our other VMAT2 inhibitors in early development."

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Neurocrine Biosciences Inc.

Company Website

12790 El Camino Real
San Diego, CA 92130

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
NBIX
47.93
  -0.63  
- 1.30%
1,136,515,000
56.97
16.15

Insider Trade Data

Date Insider Shares Type Value
10/16/2015 Bozigian, Haig P 25,000 Sell $1,194,500
10/16/2015 Coughlin, Timothy P 25,000 Sell $1,194,500
10/16/2015 Gano, Kyle 25,000 Sell $1,194,250
10/16/2015 Gorman, Kevin Charles 33,500 Sell $1,600,295
10/16/2015 Grigoriadis, Dimitri E 25,000 Sell $1,194,250

Neurocrine Biosciences Inc. Executive(s):

Kevin Gorman

  • Chief Executive Officer, President

Similar Companies

NAICS - 541711 - Research and Development in Biotechnology
Subscribe Today!